Literature DB >> 16210956

Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo.

Masayuki Sho1, Satoru Akashi, Hiromichi Kanehiro, Kaoru Hamada, Hisanori Kashizuka, Naoya Ikeda, Takeo Nomi, Yukiyasu Kuzumoto, Yoshikazu Tsurui, Hitoshi Yoshiji, Yan Wu, Daniel J Hicklin, David M Briscoe, Yoshiyuki Nakajima.   

Abstract

BACKGROUND: We have recently reported that vascular endothelial growth factor (VEGF) functions as a proinflammatory cytokine to regulate the trafficking of leukocytes into allografts in the early posttransplant period. VEGF binds two major VEGF receptors: VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR). Here, we wished to investigate the expression and function of VEGF receptors in the process of acute allograft rejection in vivo.
METHODS: We performed fully MHC-mismatched C57BL/6 (H-2b) into BALB/c (H-2d) vascularized heterotopic murine cardiac transplants and we examined the expression of VEGF and VEGF receptors by immunohistochemistry during acute allograft rejection. Next, we treated mice with specific neutralizing monoclonal antibodies against murine VEGFR-1 and VEGFR-2 and examined their effect on the development of acute allograft rejection by histology and by analysis of graft survival. The intragraft expression of cytokines and chemokines were also evaluated by quantitative real-time PCR analysis.
RESULTS: The expression of VEGF, VEGFR-1 and VEGFR-2 were significantly up-regulated during allograft rejection as compared to isografts. Administration of either anti-VEGFR-1 or anti-VEGFR-2 alone failed to inhibit allograft rejection. However, coadministration of both antibodies together inhibited leukocyte infiltration of allografts and prolonged allograft survival. Furthermore, the effect of VEGFR blockade was associated with the downregulation of intragraft cytokine and chemokine expression.
CONCLUSIONS: Our data suggest that VEGF-VEGFR interactions function in the alloimmune response in vivo. Targeting VEGFRs may represent a novel therapy to protect allografts following clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210956     DOI: 10.1097/01.tp.0000173650.83320.b1

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

Review 3.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

4.  Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

Authors:  Aninda Basu; Andre Hoerning; Dipak Datta; Monika Edelbauer; Maria P Stack; Katiana Calzadilla; Soumitro Pal; David M Briscoe
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

Review 5.  Targeting the intragraft microenvironment and the development of chronic allograft rejection.

Authors:  Olivier Dormond; Marc Dufour; Tatsuichiro Seto; Sarah Bruneau; David M Briscoe
Journal:  Hum Immunol       Date:  2012-08-03       Impact factor: 2.850

6.  Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation.

Authors:  Sarah Bruneau; Craig Bryan Woda; Kevin Patrick Daly; Leonard Boneschansker; Namrata Gargee Jain; Nora Kochupurakkal; Alan Gabriel Contreras; Tatsuichiro Seto; David Michael Briscoe
Journal:  Front Immunol       Date:  2012-04-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.